Skip to main content

Waiv

Waiv develops AI-powered diagnostic tests that help clinicians and researchers unlock tumor insights from multimodal patient dataholistic view. Its clinically validated RlapsRisk BC test for breast cancer recurrence, built on seven-plus years of medical-AI research, is designed to integrate into existing diagnostic workflows.

Paris, France · HQ
Founded 2026523K+ followers
Updated 2 days ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

As precision oncology expands, biomarker testing complexity and costs are surging while treatment decisions increasingly rely on high-dimensional data. Existing clinical diagnostics are struggling to keep pace with this scale, delaying biomarker discovery and limiting patient access to next-generation tests.

Solution

Waiv provides scalable, AI-driven diagnostic tests that streamline multimodal workflows and accelerate precision oncology. Building on clinical research legacy, the company converts high-quality, diverse data into deployable AI tests that produce morphological insights from routine pathology and clinical inputs. Its clinically validated RlapsRisk BC test is already deployed in practice, showing how Waiv's platform can move novel biomarkers into clinical use efficiently. The platform is designed to complement and future-proof existing pathology and diagnostic operations while enabling more targeted treatment decisions.

Target Audience

Primary customers are clinical diagnostic laboratories, pathology practices, oncology clinics, and biopharma companies seeking scalable precision oncology tests and biomarker discovery tools.

Features

  • AI-based diagnostic platform with clinically validated tests such as RlapsRisk BC for breast cancer recurrence risk assessment
  • Access to a large international data network providing high-quality, diverse datasets to improve model performance and clinical translation
  • Longstanding collaborations with major medical institutions and biopharma partners to co-develop targeted testing paradigms
  • Technology stack requires no major lab workflow disruption, enabling integration into standard clinical diagnostics settings
This profile is AI-generated and may contain inaccuracies.